In the last trading session, 4.45 million AbCellera Biologics Inc (NASDAQ:ABCL) shares changed hands as the company’s beta touched 0.45. With the company’s per share price at $2.52 changed hands at $0.12 or 5.00% during last session, the market valuation stood at $750.93M. ABCL’s last price was a discount, traded about -95.63% off its 52-week high of $4.93. The share price had its 52-week low at $2.11, which suggests the last value was 16.27% up since then. When we look at AbCellera Biologics Inc’s average trading volume, we note the 10-day average is 4.41 million shares, with the 3-month average coming to 3.97 million.
Analysts gave the AbCellera Biologics Inc (ABCL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 0 out of 9 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended ABCL as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. AbCellera Biologics Inc’s EPS for the current quarter is expected to be -0.14.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
Instantly ABCL was in green as seen at the end of in last trading. With action 8.15%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -13.99%, with the 5-day performance at 8.15% in the green. However, in the 30-day time frame, AbCellera Biologics Inc (NASDAQ:ABCL) is -18.71% down. Looking at the short shares, we see there were 19.9 million shares sold at short interest cover period of 4.65 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 49.6% from its current market value. According to analyst projections, ABCL’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -98.41% plunge from its current level, while the stock would need to soar -98.41% for it to hit the projected low.
AbCellera Biologics Inc (ABCL) estimates and forecasts
Year-over-year growth is forecast to reach -8.82% down from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 7.12M. 7 analysts are of the opinion that AbCellera Biologics Inc’s revenue for the current quarter will be 6.71M. The company’s revenue for the corresponding quarters a year ago was 9.95M and 7.32M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -28.43%. The estimates for the next quarter sales put growth at -8.32%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -107.74%. The 2025 estimates are for AbCellera Biologics Inc earnings to decrease by -10.53%, but the outlook for the next 5-year period is at -9.14% per year.
ABCL Dividends
AbCellera Biologics Inc is expected to release its next quarterly earnings report on 2025-Feb-26.
AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 22.88% of AbCellera Biologics Inc shares while 42.47% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 55.07%. There are 42.47% institutions holding the AbCellera Biologics Inc stock share, with BAKER BROS. ADVISORS LP the top institutional holder. As of 2024-06-30, the company held 9.3556% of the shares, roughly 27.53 million ABCL shares worth $81.48 million.
BAILLIE GIFFORD & CO holds the second largest percentage of outstanding shares, with 7.4472% or 21.91 million shares worth $64.86 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Smallcap World Fund and iShares Biotechnology ETF . With 7.54 shares estimated at $19.0 million under it, the former controlled 2.53% of total outstanding shares. On the other hand, iShares Biotechnology ETF held about 0.49% of the shares, roughly 1.45 shares worth around $3.64 million.
